X

Trial Profile

A phase III study of ALG-1001 (Luminate) for the treatment of diabetic macular oedema

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risuteganib (Primary)
Indications Diabetic macular oedema
Focus Therapeutic Use

Most Recent Events

06 Sep 2018 Route and form assumed from the phase 2 study of the same indication.
21 Aug 2018 According to an Allegro Ophthalmics media release, this trial is expected to begin in the first half of 2019.
01 Aug 2016 This profile has been created from information based on company pipeline (http://www.allegroeye.com/wp-content/uploads/2015/11/Allegro-Luminate-Clinical-Timeline-Nov-23-2015.png).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com